Hexafluorenium extension of suxamethonium block

Abstract

Clinical trials of the effectiveness of hexafluorenium (Mylaxen), as an extender of suxamethonium block, have been conducted in 645 administrations of halothane. No serious complications which could be attributed to the drug were encountered. Hista mine release after the administration of hexofluorenium was not observed. In view of the extreme efficacy and the apparent safety of the method described, its further application is considered to be justified. © 1965 John Sherratt and Son Ltd.